Partners forHealthcare
We believe in abetter future forpeople and theplanet.
At Sofinnova Partners, we focus on breakthrough innovations that have the potential to solve the world's most pressing problems. Experience, agility, and diverse points of view push us forward, driving our ability to evolve in a complex environment.
“Partners for Life” is a cornerstone of our identity: nurturing strong relationships through trust and transparency. We invest in people and science to create opportunity. We commit to long-term partnerships with entrepreneurs who are as passionate as we are about pushing the frontiers of innovation to contribute to a better future.
Founded in 1972, Sofinnova Partners has backed more than 500 companies over 50 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management.
Our Funds
Sofinnova Partners is active across the entire value chain of life sciences investments, from seed to later-stage, with a focus on healthcare and sustainability. Each of our funds is a manifestation of our ability to recognize opportunity and unlock its potential with a dedicated team and a tailored strategic approach.
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
1972
Established
50
Years of Experience
500+
Companies Backed
2.5bn
Euros in Assets Under Management
5
Distinct Fund Strategies
"We are known for being company creators. We continue to do what we know. Our strategy has evolved, but has remained consistent."
"If you treat patients, you save lives, ultimately this is going to be good for investors. We believe that by backing companies, whether early stage or later stage, that bring a product to patients — ultimately this translates into financial return."
“We have experience, a strong network, a good reputation for adding value to our portfolio companies — and the relationships between the CEOs of the portfolio companies and our partners are excellent.”
“I joined Sofinnova Partners because first of all, they have a fantastic brand in Europe, but it's easy to see it is a very strong partnership. They're loyal to each other and everyone knows they treat entrepreneurs well.”
Latest News
CinCor Pharma announces positive topline data for Phase 2 BrigHtn trial evaluating baxdrostat, its selective aldosterone synthase inhibitor, in treatment-resistant hypertension
F2G announces $70 million financing to advance development and commercialization of new antifungal agent olorofim
Noema Pharma announces recruitment of first patient in Orpheus Phase 2b Study of PDE10A inhibitor gemlapodect in adults with childhood onset fluency disorder
CinCor Pharma announces last patient randomized in Phase 2 HALO Trial and initiation of long-term extension study for Baxdrostat, a selective aldosterone synthase inhibitor, in uncontrolled hypertension
ReCor Medical and Otsuka Medical Devices announce primary endpoint met in the RADIANCE II U.S. pivotal trial of the Paradise™ System for the treatment of hypertension